Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
- Phase 1b: Safety and tolerability of the combination of polatuzumab vedotin with bendamustine and rituximab (BR) or bendamustine and obinutuzumab (BG) when administered to patients with relapsed or refractory (R/R) follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL) - Phase 1b: Determination of the Recommended Phase II Dose (RP2D) for polatuzumab vedotin given in combination with BR or with BG in patients with R/R FL or DLBCL - Phase II: Efficacy of the combination of polatuzumab vedotin plus BR compared with BR alone in patients with R/R FL or DLBCL
Inclusion criteria
- Follicular Lymphoma and Diffuse Large B-Cell Lymphoma